Empowered Funds LLC Acquires Shares of 15,849 Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Empowered Funds LLC bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 15,849 shares of the company’s stock, valued at approximately $185,000.

A number of other institutional investors and hedge funds have also made changes to their positions in NTLA. China Universal Asset Management Co. Ltd. raised its holdings in Intellia Therapeutics by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,596 shares of the company’s stock worth $252,000 after purchasing an additional 2,059 shares in the last quarter. KBC Group NV raised its holdings in Intellia Therapeutics by 62.4% during the fourth quarter. KBC Group NV now owns 6,093 shares of the company’s stock worth $71,000 after purchasing an additional 2,340 shares in the last quarter. SG Americas Securities LLC raised its holdings in Intellia Therapeutics by 85.7% during the fourth quarter. SG Americas Securities LLC now owns 44,838 shares of the company’s stock worth $523,000 after purchasing an additional 20,694 shares in the last quarter. Avanza Fonder AB purchased a new position in Intellia Therapeutics during the fourth quarter worth about $421,000. Finally, Hennion & Walsh Asset Management Inc. increased its holdings in Intellia Therapeutics by 125.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company’s stock valued at $1,411,000 after buying an additional 67,276 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 29,000 shares of company stock valued at $352,551 over the last 90 days. 3.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

NTLA has been the subject of a number of research reports. The Goldman Sachs Group reduced their price target on shares of Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating for the company in a research report on Tuesday, January 14th. Chardan Capital lifted their price target on shares of Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a research report on Monday, November 18th. Wedbush reiterated a “neutral” rating and set a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. William Blair reiterated a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. Finally, Wells Fargo & Company reduced their price target on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.71.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $12.17 on Friday. The company has a market capitalization of $1.24 billion, a P/E ratio of -2.24 and a beta of 1.80. The stock’s 50 day moving average price is $11.03 and its 200 day moving average price is $15.98. Intellia Therapeutics, Inc. has a 52 week low of $8.96 and a 52 week high of $34.87.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.